ArticleDigestive diseases and sciences2026
NCAPD2 Modulates MHC-I Antigen Presentation via the PI3K/AKT Axis to Drive Metastatic Progression in Gastric Cancer.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spatial immune niches in gastric cancer immunotherapy resistance: mechanisms and translational implications.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundImpaired major histocompatibility complex class I (MHC-I) antigen presentation constitutes a fundamental mechanism of tumor immune evasion, yet the upstream molecular drivers in gastric cancer (GC) remain enigmatic. Although non-structural maintenance of chromosomes condensin I complex subunit D2 (NCAPD2) demonstrates oncogenic potential across malignancies, its functional crosstalk with immune surveillance mechanisms remains unexplored.
methodsWe conducted transcriptome sequencing on NCAPD2-silenced GC cell lines to identify differentially expressed genes (DEGs), followed by GO and KEGG pathway analyses. Leveraging the TCGA cohort, we analyzed NCAPD2 expression patterns and evaluated its clinical relevance in GC through survival analysis. Orthogonal validation was performed via qRT-PCR and Western blot to quantify mRNA and protein levels of NCAPD2 and MHC-I. To functionally characterize the oncogenic phenotype, we employed CCK-8, wound healing, Transwell, and flow cytometry, providing a multi-parametric assessment of malignant progression mechanisms.
resultsNCAPD2 was overexpressed in GC tissues and associated with poorer patient survival. Functional characterization in GC cell lines revealed that NCAPD2 knockdown significantly inhibited malignant phenotypes, including slowed proliferation, weakened migration, reduced invasion, and enhanced apoptosis. Mechanistically, NCAPD2 downregulated MHC-I surface expression, a critical immune evasion mechanism, and this suppression was partially rescued by treatment with the PI3K inhibitor LY294002, suggesting the involvement of the PI3K/Akt signaling pathway in NCAPD2-mediated immune escape.
conclusionIn GC, elevated NCAPD2 expression is a negative prognostic marker associated with advanced tumor stage and poorer survival. Functionally, NCAPD2 promotes malignant phenotypes and downregulates MHC-I antigen presentation via the PI3K/AKT pathway, thereby facilitating immune evasion. These findings suggest NCAPD2 as a potential therapeutic target in GC.
Indexed as
Identifiers
41004034What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.